Rating Change
Oppenheimer reiterated its Outperform rating on Innoviva, Inc. (NASDAQ:INVA) on November 05, 2026.
Oppenheimer reiterated its Outperform rating on Innoviva, Inc. (NASDAQ:INVA) on November 05, 2026.

At publication ·
Innoviva, Inc. (NASDAQ:INVA) · reiterate
At a glance
Oppenheimer reiterated its Outperform rating on Innoviva, Inc. (NASDAQ:INVA) on November 05, 2026.
Innoviva, Inc. operates in the Healthcare sector. The stock currently trades at $19.24 with a market capitalization of $1.3B.
Analyst coverage from Oppenheimer provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Innoviva, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 05, 2026 | Oppenheimer | Outperform | N/A |
| Aug 07, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jun 22, 2026 | BTIG | Buy | N/A |
| Jun 01, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 26, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View INVA Stock Page
A rating of Outperform from Oppenheimer reflects the analyst's outlook on Innoviva, Inc. (NASDAQ:INVA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the INVA forecast page.
Current market data
NASDAQ · INVA
Keep reading